NVS  Novartis Ag

Exchange

NYSE

Sector

Consumer Durables

Industry

Major Pharmaceuticals

Market Cap.

174.21B

Vuru Grade

69.64/100

Current Price

$73.39
+0.765 (+1.053%)

Growth Price

$56.21
Overvalued by 23.40%

Stability Price

$14.62
Overvalued by 80.08%

Company Metrics

  • P/E 10.058
  • P/S 3.423
  • P/B 2.237
  • EPS 7.296
  • Cash ROIC 11.30%
  • Cash Ratio 0.16
  • Dividend 2.76 / 3.72%
  • Avg. Vol. 2.19M
  • Shares 2.37B
  • Market Cap. 174.21B

Company Description

Novartis AG, through its subsidiaries, engages in the research, development, manufacture, and marketing of healthcare products worldwide. Its Pharmaceuticals division offers prescription medicines in various therapeutic areas, including cardiovascular and metabolism; oncology; neuroscience and ophthalmics; respiratory; integrated hospital care; and other additional products. The company's Vaccines... more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

Will Novartis And Pharma Giants Provide Alzheimer's Cure?
Business Finance News - Feb 4, 2016
Novartis AG (ADR) (NYSE:NVS) and other market leaders are trying their best in the development of a novel drug for the comprehensive treatment of Alzheimer's disease.
European stocks for Investors: Novartis AG (ADR) (NVS), National Grid plc (ADR ...
News Oracle - 11 hours ago
27 reported that it has entered into a worldwide clinical collaboration with Novartis Pharmaceuticals (NVS) to evaluate the safety and efficacy of combining investigational agent RAD1901, a novel oral selective estrogen receptor degrader (SERD), with ...
Could Novartis AG (ADR) See a Reversal After Having a Gap Up Today?
Sonoran Weekly Review - 5 hours ago
The stock of Novartis AG (ADR) (NYSE:NVS) gapped up by $0.17 today and has $109.53 target or 49.00% above today's $73.51 share price.
Analyst's Ratings Review: Novartis AG - CWRU Observer
No One Is Above The Law; Novartis AG (ADR) Has To Pay
Business Finance News - Nov 23, 2015
Novartis AG (ADR) (NYSE:NVS) has concluded a settlement with the U.S. Justice Department regarding the drugmaker's paid rebate to the specialty pharmacies and reached an agreement to make certain changes on interactions with them.
Novartis AG (ADR) And Roche May Have To Wait Longer For “Outcome-Based ...
Business Finance News - Nov 13, 2015
The outcome-based drug pricing model is becoming a dream for Novartis AG (ADR) (NYSE:NVS) and Roche Holding Ltd. (ADR)(OTCMKTS:RHHBY).
Novartis AG (ADR) Plunges on Profit Miss
Bidness ETC - Jan 27, 2016
Novartis AG (ADR) (NYSE:NVS) reported lower-than-expected fourth quarter and full year earnings data for fiscal 2015 today, driven mostly by its struggling eye-care business and strengthened dollar.
Large Outflow of Money Witnessed in Novartis AG - Analyst Rating Reports
Novartis Slides 3% Pre-Bell – Q4 Results Miss Views; Expects Flat FY16 Core ... - WallStreet.org
Novartis AG (ADR) Entresto Clinches EU approval
Business Finance News - Nov 25, 2015
Novartis Pharmaceuticals UK's Chief Scientific Officer, Dimitrios Georgiopoulos, says, “Heart failure is a life-threatening condition that leaves a major impact on patients and their carers.
Novartis Gets EU Approval for Cardiovascular Drug Entresto - Zacks.com
Here's Why Novartis AG (ADR) Fared Better Than Others
Bidness ETC - Oct 21, 2015
Novartis AG ADR (NYSE:NVS) has signed three deals to expand its reach in the immune-oncology market. On Wednesday, Novartis announced that it had acquired Admune Therapeutics, a cancer drug maker.
Novartis (NVS) Strengthens It's Pipeline With Admune Therapeutics & XOMA - CNA Finance (press release)
Trade of the Day: NVS Stock Not Making the Cut – Sell Now
Investorplace.com - Oct 1, 2015
Novartis AG (ADR) (NVS) - This company is a leading provider of pharmaceuticals, generic drugs and health care products for consumers and animals.
Novartis AG (ADR) On Collision Course With Amgen, Inc. Again With Another ...
Bidness ETC - Oct 2, 2015
Novartis AG ADR (NYSE:NVS) and Amgen Inc. (NASDAQ:AMGN) seem to be on a collision course again as Novartis is on track to get another biosimilar candidate approved by the US Food and Drug Administration (FDA).